Abstract：Objective To study the therapeutic effect of umbilical cord mesenchymal stem cell (UC-MSC) transplantation on incomplete cervical spinal cord injury. Methods 39 patients with incomplete cervical spinal cord injury were enrolled and received 4 times of UC-MSC transplantation through the pathways of lumbar puncture. ASIA scores and the Barthel index of activities of daily living (ADL) were used to assess the motion and sensory function, musclar tention, and activities of daily living of spinal cord patients before and half a year after the transplantation. Results The patients had improvement in their motion function, sensory function, musclar tention, and activities of daily living. And the most significant improvement was motor function, the scores changed from 61±22 before operation to 70±18 at 6 month after the transplantation. No obvious adverse reactions occurred, such as surgical site infection, cerebrospinal fluid leakage and central nervous system infection, etc. 15.4% of patients experienced fever in 24 hours after operation, 7.7% of patients experienced low intracranial pressure and 5.1% of patients experienced flank and lower limber pain. Conclusions UC-MSC transplantation significantly improves the sensory function, motion function, function of urination and defecation and perspiration in patients with incomplete cervical spinal cord injury with few adverse reactions.
Sekhon L H S, Fehlings M G. Epidemiology, demographics, and pathophysiology of acute spinal cord injury [J]. Spine, 2001,26(24):2-12.
[3]
Deda H, Inci M C, Kurekci A E, et al. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation:1-year follow-up[J]. Cytotherapy, 2008,10(6):565-574.
Sekhon L H S, Fehlings M G. Epidemiology, demographics, and pathophysiology of acute spinal cord injury [J]. Spine, 2001,26(24):2-12.
[4]
Dai G H, Liu X B, Zhang Z, et al. Comparative analysis of curative effect of CT-guided stem cell transplantation and open surgical transplantation for sequelae of spinal cord injury [J]. J Transl Med, 2013,11:315-325
[3]
Deda H, Inci M C, Kurekci A E, et al. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation:1-year follow-up[J]. Cytotherapy, 2008,10(6):565-574.
[5]
Cheng H B, Liu X B, Hua R R, et al. Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury[J]. J Transl Med, 2014,12(1):253-263.
[4]
Dai G H, Liu X B, Zhang Z, et al. Comparative analysis of curative effect of CT-guided stem cell transplantation and open surgical transplantation for sequelae of spinal cord injury [J]. J Transl Med, 2013,11:315-325
[5]
Cheng H B, Liu X B, Hua R R, et al. Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury[J]. J Transl Med, 2014,12(1):253-263.
Bradshaw H B, Rimmerman N, Krey J F, et al. Sex and hormonal cycle differ-ences in rat brain levels of pain-related cannabimimetic lipid mediators [ J]. Am J PhysiolRegul IntegrComp Physiol, 2006,291(2):349-358.
Bradshaw H B, Rimmerman N, Krey J F, et al. Sex and hormonal cycle differ-ences in rat brain levels of pain-related cannabimimetic lipid mediators [ J]. Am J PhysiolRegul IntegrComp Physiol, 2006,291(2):349-358.
[9]
An Y H, Tsang K S, Zhang H. Potential of stem cell based therapy and tissue engineering in the regeneration of central nervous system [J]. Biomed Mater, 2006,1(2):R38-R44.
[9]
An Y H, Tsang K S, Zhang H. Potential of stem cell based therapy and tissue engineering in the regeneration of central nervous system [J]. Biomed Mater, 2006,1(2):R38-R44.
[10]
Sun C R, Wang C C, Tsang K S, et al. Modulation and impact of class I major histocompatibility complex by neural stem cell-derived neurotrophins on neuroregeneration [J]. Med Hypotheses, 2007,68(1):176-179.
[10]
Sun C R, Wang C C, Tsang K S, et al. Modulation and impact of class I major histocompatibility complex by neural stem cell-derived neurotrophins on neuroregeneration [J]. Med Hypotheses, 2007,68(1):176-179.
[11]
Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus [J]. Arthritis Rheum,2010,62(8):2467-2475.
[11]
Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus [J]. Arthritis Rheum,2010,62(8):2467-2475.
[12]
Tysseling-Mattiace V M, Sshni V, Niece K L, et al. Self-assembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury[J]. J Neurosci, 2008,28(14):3814-3823.
[12]
Tysseling-Mattiace V M, Sshni V, Niece K L, et al. Self-assembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury[J]. J Neurosci, 2008,28(14):3814-3823.
[13]
Wu K H, Yang S G, Zhou B, et al. Human umbilical cord derived stem cells for the injured heart [J]. Med hypoth, 2007, 68(1): 94-97.
[13]
Wu K H, Yang S G, Zhou B, et al. Human umbilical cord derived stem cells for the injured heart [J]. Med hypoth, 2007, 68(1): 94-97.
[14]
Alberti E, Los M, Garcia R, et al. Prolonged survival and expression of neural markers by bone marrow-derived stem cells transplanted into brain lesions [J]. Med Sci Monit, 2009,15(2):BR47-54.
[14]
Alberti E, Los M, Garcia R, et al. Prolonged survival and expression of neural markers by bone marrow-derived stem cells transplanted into brain lesions [J]. Med Sci Monit, 2009,15(2):BR47-54.
[15]
Peru R L, Mandrycky N, Nait-Oumesmar B, et al. Paving the axonal highway: from stem cells to myelin repair [J]. Stem Cell Rev, 2008,4(4):304-318.
[15]
Peru R L, Mandrycky N, Nait-Oumesmar B, et al. Paving the axonal highway: from stem cells to myelin repair [J]. Stem Cell Rev, 2008,4(4):304-318.
[16]
Alenxanian A R, Mainman D J, Kurpad S N, et al. In vitro and in vivo characterization of neurally modified mesenchymal stem cells induced by epigenetic modifiers and neural stem cell environment [J]. Stem Cells Dev, 2008,17(6):1123-1130.
[16]
Alenxanian A R, Mainman D J, Kurpad S N, et al. In vitro and in vivo characterization of neurally modified mesenchymal stem cells induced by epigenetic modifiers and neural stem cell environment [J]. Stem Cells Dev, 2008,17(6):1123-1130.
[17]
Substrate K, Keung A J, Irwin E F, et al. Substrate modulus directs neural stem cell behavior [J]. Biophys J, 2008,95(9):4426-4438.
[17]
Substrate K, Keung A J, Irwin E F, et al. Substrate modulus directs neural stem cell behavior [J]. Biophys J, 2008,95(9):4426-4438.
[18]
Xuan A G, Long D H, Gu H G, et al. BDNF improves the effects of neural stem cells on the rat model of Alzheimer’s disease with unilateral lesion of fimbria-fornix [J]. Neurosci Lett, 2008,440(3):331-335.
[18]
Xuan A G, Long D H, Gu H G, et al. BDNF improves the effects of neural stem cells on the rat model of Alzheimer’s disease with unilateral lesion of fimbria-fornix [J]. Neurosci Lett, 2008,440(3):331-335.
[19]
Sasaki H, Ishikawa M, Tanaka N, et al. Administration of human peripheral blood-derived CD133+ cells accelerates functional recovery in a rat spinal cord injury model [J]. Spinal, 2009,34(3):249-254.
[20]
Oz Oyar E, Kardes O, Korkma A, et al. Effects of vascular endothelial growth factor on ischemic spinal cord injury caused by aortic cross-clamping in rabbits[J]. J Surg Res, 2009,151(1):94-99.
[19]
Sasaki H, Ishikawa M, Tanaka N, et al. Administration of human peripheral blood-derived CD133+ cells accelerates functional recovery in a rat spinal cord injury model [J]. Spinal, 2009,34(3):249-254.
[20]
Oz Oyar E, Kardes O, Korkma A, et al. Effects of vascular endothelial growth factor on ischemic spinal cord injury caused by aortic cross-clamping in rabbits[J]. J Surg Res, 2009,151(1):94-99.
[21]
Hess D C, Borlongan C V. Stem cells and neurological diseases [J]. Cell Prolif, 2008,41(Suppl 1):94-114.
[22]
Walker T L, White A, Black D M, et al. Latent stem and progenitor cells in the hippocampus are activated by neural excitation [J]. J Neurosci, 2008,28(20):5240-5247.
[21]
Hess D C, Borlongan C V. Stem cells and neurological diseases [J]. Cell Prolif, 2008,41(Suppl 1):94-114.
[23]
Walker P A, Harting M T, Shah S K, et al. Progenitor cell therapy for the treatment of central nervous system injury: a review of the state of current clinical trials [J]. Stem Cells Int, 2010,2010(20):1-8.
[22]
Walker T L, White A, Black D M, et al. Latent stem and progenitor cells in the hippocampus are activated by neural excitation [J]. J Neurosci, 2008,28(20):5240-5247.
[23]
Walker P A, Harting M T, Shah S K, et al. Progenitor cell therapy for the treatment of central nervous system injury: a review of the state of current clinical trials [J]. Stem Cells Int, 2010,2010(20):1-8.
2015, Vol. 26 
